摘要
目的:探讨胃癌表皮生长因子受体(EGFR)免疫组织化学表达与EGFR基因突变的关系及其临床意义。方法:对105例手术切除的胃癌组织应用免疫组化方法检测EGFR蛋白表达,聚合酶链反应-单链构象多态性分析(PCR-SSCP)检测EGFR基因突变的情况,分析EGFR蛋白表达与EGFR基因突变间的相关性。结果:免疫组织化学检测结果显示,105例胃癌中49例EGFR阳性表达,表达率为46.67%;而发生EGFR基因突变的仅3例,突变率为2.86%。EGFR蛋白表达与其基因的突变无相关性(P>0.05)。结论:EGFR的蛋白表达与其基因突变无相关性,EGFR基因突变可能不是蛋白表达增高的主要机制,不能作为筛选EGFR酪氨酸激酶抑制剂治疗胃癌的生物学指标。
Objective： To investigate the gastric cancer, epidermal growth factor receptor（EGFR） expression and chemical relationship between mutation and clinical significance of EGFR gene immunohistochemistry. Methods： 105 cases of gastric cancer tissues using immunohistochemistry operation excision method to detect the expression of EGFR protein, the polymerase chain reaction single strand conformation polymorphism（PCR-SSCP） to detect EGFR gene mutation, analysis of relationship between the expression of EGFR protein and EGFR gene mutation. Results： The results of immunohistochemistry showed that in 105 cases of gastric carcinoma, 49 cases of EGFR positive expression, the expression rate was 46.67%; and the occurrence of EGFR gene mutation in only 3 patients, the mutation rate was 2.86%. The expression of EGFR protein and its gene mutation has no correlation（P〉0.05）. Conclusion： The expression of EGFR protein and its gene mutation has no correlation, EGFR gene mutation might not be the main mechanism of protein expression increased, can not be used as the screening of inhibitors in the treatment of gastric cancer biological indicator of EGFR tyrosine kinase.
出处
《中国医药导刊》
2015年第7期651-652,654,共3页
Chinese Journal of Medicinal Guide
基金
甘肃省卫生厅2014年重点研究课题
课题编号:GSWSKY-2014-40
课题名称:上消化道癌及癌前疾病内镜干预研究
关键词
胃癌
EGFR
基因突变
免疫组化
Gastric carcinoma
EGFR
Gene mutation
Immunohistochemistry
